LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NYXH
Nyxoah S.A.
There isn't enough reported data to score NYXH yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NYXH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
NYXH's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NYXH PE Valuation
NYXH has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NYXH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect NYXH's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NYXH on earnings quality, reporting a profit while its opponent remains loss making.
NYXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.41 | -$0.07 |
| Q1 2026 | -$2.38 | -$0.17 |
| Q4 2025 | -$2.63 | -$0.62 |
| Q3 2025 | -$2.49 | -$0.57 |
| Q2 2025 | -$2.34 | -$0.67 |
| Q1 2025 | -$2.21 | -$0.52 |
| Q4 2024 | -$2.01 | -$0.28 |
| Q3 2024 | -$1.92 | -$0.04 |
NYXH lost $2.41 per share over the past year, about the same as its loss the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NYXH on profitability, with a higher operating margin.
NYXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.5M | +473% |
| Q1 2026 | $8.2M | +592% |
| Q4 2025 | $6.3M | +347% |
| Q3 2025 | $2.2M | +56% |
| Q2 2025 | $1.5M | +74% |
| Q1 2025 | $1.2M | -13% |
| Q4 2024 | $1.4M | -31% |
| Q3 2024 | $1.4M | +30% |
NYXH's revenue has grown year over year for five quarters in a row: $9M last quarter, up 473% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -268% | +1213 points |
| Q1 2026 | -322% | +1617 points |
| Q4 2025 | -324% | +1126 points |
| Q3 2025 | -1227% | -44 points |
| Q2 2025 | -1481% | +245 points |
| Q1 2025 | -1940% | -940 points |
| Q4 2024 | -1450% | -856 points |
| Q3 2024 | -1183% | -58 points |
NYXH's operating margin was −268% last quarter, up 1213 points from the same quarter a year ago, near the top of its range since 2020.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NYXH on cash generation, producing positive trailing cash flow while its opponent burns cash.
NYXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$19.8M | -$639.9K |
| Q1 2026 | -$24.8M | -$4M |
| Q4 2025 | -$14.6M | +$682K |
| Q3 2025 | -$22.8M | -$7M |
| Q2 2025 | -$19.2M | -$5.2M |
| Q1 2025 | -$20.8M | -$4.5M |
| Q4 2024 | -$15.3M | -$369.9K |
| Q3 2024 | -$15.8M | -$40K |
NYXH has burned cash in almost every quarter: −$82M over the past year, against −$71M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NYXH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NYXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +13.8M shares |
| 1 year | +52% | +19.6M shares |
| 3 years | +99% | +28.4M shares |
| 5 years | +158% | +34.9M shares |
| Available history | +376% | +45M shares |
NYXH has 57M diluted shares, up 52% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NYXH hasn't bought back shares in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NYXH Net Leverage
NYXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NYXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.6 | Oversold |
| Stochastic | 6.9 | Oversold |
NYXH's weekly RSI is 27 (oversold) and its Stochastic is 7 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NYXH PE vs Healthcare Sector
NYXH has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NYXH on trend strength, trading above more of its moving averages.
NYXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 17% below |
| 20 week MA | $1.37 | 34% below |
| 50 week MA | $2.70 | 67% below |
| 100 week MA | $5.04 | 82% below |
| 200 week MA | $6.61 | 86% below |
NYXH is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NYXH on returns for 2026, with the stronger performance.
NYXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $21.0 | -12% |
| 2022 | $21.0 | $5.20 | -75% |
| 2023 | $5.20 | $4.64 | -11% |
| 2024 | $4.64 | $8.00 | +72% |
| 2025 | $8.00 | $4.47 | -44% |
| 2026 YTD | $4.47 | $0.90 | -80% |
NYXH has finished lower in four of the last five years. It's down 80% so far in 2026.